Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes

American Heart Journal

Volumn 148, Issue 6, 2004, Pages 1034-1040

  Kolek, Matthew J ^a   Carlquist, John F ^a,b   Muhlestein, Joseph B ^a,b   Whiting, Bryant M ^a   Horne, Benjamin D ^a   Bair, Tami L ^a   Anderson, Jeffrey L ^a,b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TOLL LIKE RECEPTOR 4;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE FREQUENCY; GENE FUNCTION; GENETIC RISK; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT SELECTION; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; REAL TIME POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE; WILD TYPE;

AGED; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LOGISTIC MODELS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RECEPTORS, CELL SURFACE; RISK FACTORS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 10644236977     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.05.049     Document Type: Article

References (36)

1. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med. 340:1999;115-126
2. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 105:2002;1135-1143
3. Morrow D.A., Ridker P.M. Inflammation in cardiovascular disease. Topol E.J. Textbook of cardiovascular medicine. 1999;1-12 Lippincott, Williams & Wilkins, Cedar Knolls (NJ)
4. Zebrack J.S., Anderson J.L. The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease. Review. Curr Cardiol Rep. 4:2002;278-288
5. Anderson J.L., Muhlestein J.B. The role of infection. Theroux P. Acute coronary syndromes a companion to braunwald's heart disease. 2003;88-107 WB Saunders, Philadelphia (PA)
6. Biondi-Zoccai G.G., Abbate A., Liuzzo G., et al. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol. 41:2003;1071-1077
7. Pradhan A.D., Manson J.E., Rifai N., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 286:2001;327-334
8. Freeman D.J., Norrie J., Caslake M.J., et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 51:2002;1596-1600
9. Keavney B., McKenzie C., Parish S., et al. Large-scale test of hypothesized associations between the angiotensin-converting enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet. 355:2000;434-442
10. Glazier A.M., Nadeau J.H., Aitman T.J. Finding genes that underlie complex traits. Science. 298:2002;2345-2349
11. Yamada Y., Izawa H., Ichihara S., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 347:2002;1916-1923
12. Hegele R.A. SNP judgments and freedom of association. Arteroscler Thromb Vasc Biol. 22:2002;1058-1061
13. Anderson J.L., Carlquist J.F., Horne B.D., et al. Cardiovascular pharmacogenomics: current status, future prospects. J Cardiovasc Pharmacol Therapeut. 8:2003;71-83
14. Anderson J.L., Carlquist J.F. Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk Do they add up yet? J Am Coll Cardiol. 41:2003;1990-1993
15. MacKay I., Rosen F.S. Innate immunity. N Engl J Med. 343:2000;338-344
16. Medzhitov R., Preston-Hurlbury P., Janeway C.A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 388:1997;394-397
17. Kopp E.B., Medzhitov R. The toll-receptor family and control of innate immunity. Curr Opin Immunol. 11:1999;13-18
18. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2:2001;675-680
19. Zarember K.A., Gogowske P.J. Tissue expression of human toll-like receptors and differential regulation of toll-like receptors mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 168:2002;554-561
20. Chow J.C., Young D.W., Golenbock D.T., et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 274:1999;10689-10692
21. Kiechl S., Lorenz E., Reindl M., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 347:2002;185-192
22. Arbour N.C., Lorenz E., Schutte B.C., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 25:2000;187-191
23. Boekholdt S.M., Agema W.R., Peters R.J., et al. Variants of toll-like receptor 4 modify efficacy of statin therapy and the risk of cardiovascular events. Circulation. 107:2003;2416-2421
24. Taylor G.S., Muhlestein J.B., Wagner G.S., et al. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J. 136:1998;792-803
25. Anderson J.L., King G.J., Thomson M.J., et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 30:1997;1206-1211
26. Applied Biosystems. (Accessed at http://www.appliedbiosystems. com/products/productdetail.cfm?prod_id=1541.)
27. Anderson J.L., Carlquist J.F., Muhlestein J.B., et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol. 32:1998;35-41
28. Muhlestein J.B., Horne B.D., Carlquist J.F., et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation. 102:2000;1917-1923
29. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 107:2003;499-511
30. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 107:2003;363-369
31. Fuster V., Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146
32. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 20:1997;1183-1197
33. Grundy S.M., Howard B., Smith S.J., et al. Prevention Conference VI Diabetes and Cardiovascular Disease: executive summary: conference proceedings for healthcare professionals from a special writing group of the American Heart Association. Circulation. 105:2002;2231-2239
34. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 48:1999;1-9
35. Ameziane N., Beillat T., Verpillat P., et al. Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arteroscler Thromb Vasc Biol. 23:2003;e61-64
36. Yang I.A., Holloway J.W., Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis. 170:2003;187-190